Quralis

Quralis company information, Employees & Contact Information

Explore related pages

Related company profiles:

At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers.

Company Details

Employees
95
Founded
-
Address
35 Cambridgepark Dr,
Phone
(+1) 617.682.6015
Email
in****@****lis.com
Industry
Biotechnology
HQ
Cambridge, Massachusetts
Looking for a particular Quralis employee's phone or email?

Quralis Questions

News

QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers - PR Newswire

QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers PR Newswire

Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome - Business Wire

Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome Business Wire

QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS - PR Newswire

QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS PR Newswire

Eli Lilly adds ALS drug prospect with QurAlis deal - BioPharma Dive

Eli Lilly adds ALS drug prospect with QurAlis deal BioPharma Dive

QurAlis Opens New Global Headquarters - Genetic Engineering and Biotechnology News

QurAlis Opens New Global Headquarters Genetic Engineering and Biotechnology News

Biotech Firm QurAlis Opens New 30,000-SF Global Headquarters in Cambridge’s Alewife Biotech Park - Boston Real Estate Times

Biotech Firm QurAlis Opens New 30,000-SF Global Headquarters in Cambridge’s Alewife Biotech Park Boston Real Estate Times

Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect - Fierce Biotech

Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect Fierce Biotech

QurAlis Appoints Three New Members to Leadership Team - citybiz

QurAlis Appoints Three New Members to Leadership Team citybiz

QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed - PR Newswire

QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed PR Newswire

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases - PR Newswire

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases PR Newswire

QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD - PR Newswire

QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD PR Newswire

QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies - PR Newswire

QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies PR Newswire

QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing - PR Newswire

QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing PR Newswire

QurAlis Announces Expansion of its Selective Kv7.2/7.3 Ion Channel Opener, QRL-101, Into Epilepsy - PR Newswire

QurAlis Announces Expansion of its Selective Kv7.2/7.3 Ion Channel Opener, QRL-101, Into Epilepsy PR Newswire

QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform - PR Newswire

QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform PR Newswire

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia - PR Newswire

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia PR Newswire

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - PR Newswire

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS PR Newswire

QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors - PR Newswire

QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors PR Newswire

QurAlis' FlexASOs Show High Potency and Improved Safety Over Standard ASOs - PR Newswire

QurAlis' FlexASOs Show High Potency and Improved Safety Over Standard ASOs PR Newswire

QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board - PR Newswire

QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board PR Newswire

ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ticket to LabCentral - Fierce Biotech

ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ticket to LabCentral Fierce Biotech

QurAlis Spins out Med Device Company EnClear to Target ALS - BioSpace

QurAlis Spins out Med Device Company EnClear to Target ALS BioSpace

Amgen backs Harvard professors’ ALS startup QurAlis - Fierce Biotech

Amgen backs Harvard professors’ ALS startup QurAlis Fierce Biotech

Top Quralis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant